ASX Tech Stocks: Data3 gains on results forecast, while resignations & appointments mark the new year
The share price in software company Data#3 Limited (ASX:DTL) has risen ~12% in morning trade to $6.50 after it said its FY22 results are expected to be better than forecast.
Net profit before tax (NPBT) for the first half of FY22 is expected to be slightly ahead of the top end of the $15 to $18 million guidance range.
Earnings per share for Data#3 is also expected to be approximately 30% higher than the record 1H FY21 results.
Data#3 delivers a range of integrated software solutions spanning cloud, modern workplace, security, data, analytics and connectivity. The company’s board will announce the detailed results and an interim dividend on February 17.
Resignations & appointments
Maybe it was time off with family, kicking back on beach holidays or having time to reflect on what you want out of life, but today’s ASX announcements have seen key resignations and appointments at various small and midcaps.
Symbio Holdings (ASX:SYM) today announced the resignation of its CFO Chris Last, who has decided to take a career break to spend more time with family.
Symbio Holdings, previously MNF Group (ASX:MNF), last year entered a deal with fibre network company Superloop (ASX:SLC), who became its exclusive supplier of wholesale nbn aggregation services via its Superloop Connect platform.
Last will stay on until March 22 to deliver the company’s 1H FY2022 results and ensure a smooth transition to his successor, yet to be appointed.
Natural tissue regeneration specialist Osteopore (ASX:OSX) also announced its CFO Carl Rundle’s resignation to “pursue other opportunities”.
Rundle played a key role in growing Osteopore’s finance team and had extensive ASX experience to help guide the company since it listed in 2019. Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Rundle will stay on at Osteopore until completion of its full 2021 results, with the search underway for his replacement.
In appointments, Compumedics (ASX:CMP) has announced PAC Partners Securities executive director Paul Jensz will become a company director effective immediately, subject to shareholder approval at the company’s next general meeting.
Jenz’s experience as an investment banker and analyst covering large cap health sector market leaders like CSL, Cohlear and Sonic is seen as an asset to the company.
He will help guide Compumedics, which designs and manufactures technologies for the diagnosis of sleep disorders, across a several key areas including international capital markets, the company said.